Save the Date
International Webinar
CDK4/6 Inhibition in Early and Advanced Breast Cancer 2025
Updated Evidence, Controversy & Expert Debate(s)
| Date: | 29.10.2025 |
| Start/End: | 17:00 – 19:00 |
| Location: | online |
| Program | Download |
| Calendar | Download iCal-File |
28.06.2025
We invite you to join the upcoming ABCSG webinar dedicated to the evolving role of CDK4/6 inhibitors in the treatment of hormone receptor-positive (HR+) breast cancer. This year’s session will explore both metastatic and early-stage settings, with a focus on recent trial results, clinical controversies, and practical decision-making.
The event will open with a dynamic debate on the long-term use of CDK4/6 inhibitors in metastatic breast cancer, featuring ABCSG experts Rupert Bartsch and Gabriel Rinnerthaler. Moderated by Marija Balic, this session aims to highlight differing perspectives on a key therapeutic question.
In the second part of the program, we shift focus to the adjuvant setting. Christian Singer and Valentina Guarneri will present the latest data from the NATALEE and monarchE trials, followed by insights from Patrick Neven on translating this evidence into clinical practice.
A concluding panel discussion will bring together all speakers along with additional experts – Daniel Egle, Georg Pfeiler, Gunda Pristauz-Telsnigg, and Kathrin Strasser-Weippl – to discuss how new findings impact clinical decision-making. ABCSG President Michael Gnant will moderate and wrap up the session with key take-home messages.
We encourage you to register and take part in the live discussions and Q&A segments. This is a valuable opportunity to engage directly with leading international experts and stay up to date with the latest developments in breast cancer treatment.
We look forward to welcoming you to this timely and highly relevant webinar!
Share on